Genmab Buyback And Abkinley Approval Reframe Growth And Risk Balance

Simply Wall St

Tue, February 24, 2026 at 2:08 PM GMT+9 4 min read

In this article:

GMAB

-0.07%

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Genmab (CPSE:GMAB) has launched a new share buyback program linked to its Restricted Stock Unit commitments.

The company reported strong revenue growth and higher proprietary drug sales alongside the buyback announcement.

Genmab added three new Phase 3 trials to its pipeline and received FDA approval for Abkinley in a new cancer indication.

Management also reported a setback in one Phase 3 study while highlighting broader progress in its development programs.

Genmab, known for its antibody based cancer therapies, sits at the crossroads of biotech research and commercial drug sales. For investors, the mix of fresh Phase 3 trials, an additional FDA approval, and a new buyback program creates a cluster of events that can influence how the CPSE:GMAB story is viewed. The combination of pipeline updates and capital allocation choices gives investors more moving parts to track than a simple earnings release.

From here, the key questions for holders are how effectively Genmab converts its expanded late stage pipeline into approved products and how disciplined it remains with capital returns. The latest buyback and Abkinley decision provide fresh reference points for judging management priorities and execution as new clinical readouts arrive over time.

Stay updated on the most important news stories for Genmab by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Genmab.

CPSE:GMAB Earnings & Revenue Growth as at Feb 2026

Is Genmab’s dividend sustainable? Check out what every dividend investor needs to know in our dividend analysis.

The new share buyback program sits alongside Genmab’s earnings and pipeline update as a signal about how management is thinking about capital returns. While the company is not highlighting a cash dividend here, buying back up to 342,130 shares for up to DKK 725 million, primarily to meet Restricted Stock Unit obligations, still matters for you if you care about per share value. It shows Genmab using its balance sheet to offset dilution from equity-based pay rather than letting the share count drift higher.

How This Fits Into The Genmab Narrative

The buyback and strong 2025 sales of US$3.72b, supported by higher proprietary medicine sales such as Abkinley, line up with the narrative that recurring royalties and owned products can support long term earnings power.

The guidance for 2026 operating profit of US$0.9b to US$1.4b, compared with US$1.3b in 2025, reminds investors that heavier investment in late stage trials can pressure profitability, which is one of the concerns already raised in the narrative.

The new buyback, focused on Restricted Stock Units, is not directly reflected in the narrative’s discussion of share count growth and could influence how you think about future dilution and capital allocation quality.

 






Story Continues  

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Genmab to help decide what it’s worth to you.

The Risks and Rewards Investors Should Consider

⚠️ Operating profit guidance that brackets a possible step down from 2025 levels highlights the risk that higher R&D and commercialization costs weigh on margins.

⚠️ The EPCOR DLBCL-1 trial’s miss on overall survival keeps clinical and regulatory risk in focus, especially when peers like Roche or Novartis are also advancing oncology pipelines.

🎁 19% revenue growth in 2025, with a 54% surge in proprietary medicine sales, supports the view that Genmab is building a more diversified commercial base beyond partnered royalties.

🎁 The buyback to cover Restricted Stock Units, together with strong cash generation, points to a management team that is attentive to dilution and shareholder returns, a plus for investors who care about capital discipline.

What To Watch Going Forward

From here, keep an eye on how quickly the new Phase 3 trials progress and whether further approvals, like Abkinley in second line follicular lymphoma, translate into sustained product sales. Watch the actual execution of the buyback and any future commentary on broader return-of-capital plans, including the possibility of dividends or larger repurchase programs. It is also worth tracking how Genmab’s royalty streams on partnered drugs compare with oncology peers such as Roche and Bristol Myers Squibb, given the importance of these payments to cash flow. Finally, monitor updates on the EPCOR DLBCL-1 regulatory discussions, as the outcome will help frame how much weight to place on the broader epcoritamab program.

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Genmab, head to the community page for Genmab to never miss an update on the top community narratives.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include GMAB.CO.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info